Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the consistency of immune responses to three different batches of an investigational chickenpox vaccine called VNS vaccine in healthy children aged 12 to 15 months who have not had chickenpox or received a chickenpox vaccine before. The study also compares the safety and immune response of the VNS vaccine to an approved chickenpox vaccine known as Varivax. This Phase 3a study is sponsored by GlaxoSmithKline and aims to better understand the immune protection provided by these vaccines. Participants are randomly assigned to receive one dose of either one of the three investigational VNS vaccine lots or one of two lots of the marketed Varivax vaccine. Along with the chickenpox vaccine, they also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine HAV, and a pneumococcal conjugate vaccine PCV which could be PCV 13, Vaxneuvance, or PCV 20 depending on availability and country recommendations. All vaccines are given on Day 1 of the study. During the study, researchers monitor the participants immune responses by measuring antibodies against varicella zoster virus VZV and other vaccine components at Day 43. They also track safety by recording any side effects or adverse events from Day 1 to Day 181. The study includes diary reports by parents and regular clinical evaluations to assess immune response and safety outcomes. Participation involves a single vaccination visit and follow-up assessments over approximately six months.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.
Actively Recruiting
Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating whether ataciguat can slow the progression of moderate calcific aortic valve stenosis CAVS in adults aged 50 and older. This study is conducted in two parts Part A focuses on whether ataciguat reduces calcium buildup in the aortic valve over 24 weeks, while Part B examines if the drug slows narrowing of the valve area and improves peak oxygen consumption over 48 weeks. Safety, tolerability, and how the body processes ataciguat are also assessed. Participants receive either ataciguat or a placebo daily for up to 156 weeks. Part A enrolls about 132 participants, and Part B will begin after Part A completes, enrolling around 1144 participants. Part B includes additional evaluation of heart function and ability to exercise. The study uses a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants undergo imaging tests like CT scans and echocardiograms to measure valve calcium and valve area. Cardiopulmonary exercise testing CPET is used to assess peak oxygen consumption. Researchers also monitor heart function, symptoms, and quality of life using questionnaires. Assessments occur mainly at baseline, Week 24, and Week 48, with long-term follow-up to 156 weeks for safety and efficacy. The studys total duration extends to 2030.
Actively Recruiting
Researchers are evaluating Baroreflex Activation Therapy BAT using the Barostim System in adults with heart failure classified as NYHA Functional Class II or III, with reduced heart function LVEF under 50% and specific blood marker levels NT-proBNP under 5,000 pgmL despite receiving usual guideline-directed medical therapies. The study aims to assess the safety and effectiveness of adding the Barostim System to usual care compared to usual care alone, particularly focusing on reducing all-cause mortality and heart failure-related events like cardiac transplant or worsening heart failure. Participants are randomly assigned to either receive the Barostim System device implant plus usual care or continue with usual care medical management without the device. The study follows participants with these two groups in parallel, monitoring outcomes for up to 24 months after treatment begins. The Barostim System delivers BAT via an implanted device, and the study includes safety monitoring within 180 days post-implant. Throughout the study, participants undergo various assessments including quality of life evaluations, six-minute hall walk tests, laboratory tests for NT-proBNP levels, and tracking of hospitalizations and mortality over 24 months. These measurements help researchers understand the impact of the therapy on heart failure symptoms and patient well-being. Participants must comply with medication management and follow-up visits as required, while safety and effectiveness endpoints are carefully monitored by the research team.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Healthy Volunteer
This research evaluates the growth and tolerance of infants consuming a new extensively hydrolyzed cow milk protein formula compared to a currently marketed extensively hydrolyzed cow milk protein formula. The study focuses on healthy, term infants aged approximately 10 to 14 days at enrollment, aiming to show that the investigational formula supports typical growth and is well tolerated. Secondary goals include examining feeding tolerance, stool characteristics, intake amounts, and any health issues arising during the study. Participants will be randomly assigned to receive either the investigational extensively hydrolyzed casein formula made with a new manufacturing process or a commercially available extensively hydrolyzed casein formula. Both formulas have the same nutritional content per 100 kcal. The study formula feeding will continue through approximately 126 days of age. During the study, infants growth measurements such as weight gain, body length, and head circumference will be tracked up to 131 days of age. Researchers will also monitor stool characteristics, formula intake, tolerance signs like spit-up or fussiness, and any medically confirmed adverse events. Caregivers will be supported with remote visits and assessments, including the use of reliable internet for study participation.
1-10 of 19
1